PD-1/PD-L1抑制剂免疫相关性不良反应及其处理综述

Management of immune-related adverse events of PD-1/PD-L1 inhibitors therapy

免疫检查点抑制剂用于治疗恶性肿瘤疗效显著,已逐渐成为主流的抗肿瘤手段。其中PD-1/PD-L1抑制剂已广泛应用于非小细胞肺癌、恶性黑色素瘤、肾癌等的治疗,延长了患者总生存期。然而PD-1/PD-L1抑制剂同时也会引起免疫相关性不良反应,可以累及人体的任何器官,严重时可威胁生命。本文对PD-1/PD-L1抑制剂引起的免疫相关性不良反应及其处理进行综述,为临床的诊断及治疗提供依据。

Immune checkpoint inhibitors have shown impressive efficacy on malignant tumors and are becoming a mainstay in the treatment of cancer entities. PD-1/PD-L 1 inhibitors have been widely used for the treatment of non-small cell lung cancer, malignant melanoma, renal carcinoma and other cancers, and they have prolonged the overall survival of patients. Meanwhile, they can induce immune-related adverse events （irAEs）. These side effects can involve any organ and sometimes can be life-threatening. We review the irAEs of PD-1/PD-L 1 inhibitors therapy in various organs and the corresponding management, which can provide theory basis for clinical diagnosis and treatment.